Home » Pre-increment!Jiuzhou Pharmaceutical: It is estimated that the annual net profit in 2021 will be about 609 million yuan to about 685 million yuan, a year-on-year increase of 60% to 80%.

Pre-increment!Jiuzhou Pharmaceutical: It is estimated that the annual net profit in 2021 will be about 609 million yuan to about 685 million yuan, a year-on-year increase of 60% to 80%.

by admin

Summary

[JiuzhouPharmaceutical:Itisestimatedthattheannualnetprofitin2021willbeabout609millionyuantoabout685millionyuananincreaseof60%to80%year-on-year]Jiuzhou Pharmaceutical (SH 603456) released a performance forecast on the evening of January 18. The company expects 2021 The annual net profit attributable to shareholders of the listed company is about 609 million yuan to about 685 million yuan, which will increase by about 228 million yuan to about 304 million yuan compared with the same period of the previous year, a year-on-year increase of 60% to 80%. (Daily Economic News)


  Jiuzhou Pharmaceutical(SH 603456, closing price: 51.38 yuan) Released on the evening of January 18performanceAnnouncement, the company expects to be attributable to listed companies in 2021shareholderofnet profitFrom about 609 million yuan to about 685 million yuan, compared with the same period of the previous year, it will increase by about 228 million yuan to about 304 million yuan, an increase of 60% to 80%. The main reason for the change in performance was the impact of the main business. This year’s performance growth is mainly due to the continuous growth of the company’s CDMO business. In 2021, based on years of industry leading advantages and platform effects, the company will continue to deepen the CDMO business, always adhere to customer demand-oriented, in-depth expansion of customer pipelines and product pipelines, and steadily improve the company’s R&D Ability and product delivery ability, further realize the improvement and increment of CDMO business, and realize the sustained and rapid development of the company’s CDMO business. The impact of non-operating profit and loss. The company’s non-recurring gains and losses are mainly due to the impact of government subsidies and forward foreign exchange settlement and sales. After deducting the impact of income tax, the amount of non-recurring gains and losses increased by about 2.3 million yuan over the same period of the previous year.

See also  Songcheng Performing Arts: 2021 annual profit of 258 million-358 million yuan to turn losses into profits from a year-on-year basis – yqqlm

According to the 2020 annual report,Jiuzhou Pharmaceutical‘s main business isChemical materialsThe production and sales of medicines and intermediates accounted for 93.93% of the revenue.

  Jiuzhou PharmaceuticalThe general manager and chairman of the board are Hua Lirong, female, 54 years old, with a master’s degree.

(Article source: Daily Economic News)


Article source: Daily Economic News

Responsible editor: 91

Original title: Pre-increment! Jiuzhou Pharmaceutical: It is estimated that the annual net profit in 2021 will be about 609 million yuan to about 685 million yuan, a year-on-year increase of 60% to 80%

Solemnly declare: Oriental Fortune.com releases this information for the purpose of disseminating more information and has nothing to do with the position of this site.

report

Share to WeChat Moments

Open WeChat,

Click “Discover” at the bottom

Use “Sweep”

You can share the webpage to the circle of friends

Scan the QR code to follow

Oriental Fortune official website WeChat

.

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy